Equities research analysts predict that Cerner Co. (NASDAQ:CERN) will report earnings of $0.61 per share for the current fiscal quarter, according to Zacks. Eleven analysts have issued estimates for Cerner’s earnings, with the highest EPS estimate coming in at $0.66 and the lowest estimate coming in at $0.60. Cerner also reported earnings of $0.61 per share in the same quarter last year. The business is expected to announce its next earnings results on Thursday, February 8th.
According to Zacks, analysts expect that Cerner will report full-year earnings of $2.42 per share for the current year, with EPS estimates ranging from $2.41 to $2.50. For the next financial year, analysts expect that the business will report earnings of $2.61 per share, with EPS estimates ranging from $2.54 to $2.77. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Cerner.
Cerner (NASDAQ:CERN) last announced its quarterly earnings data on Thursday, October 26th. The company reported $0.61 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.01). The firm had revenue of $1.28 billion for the quarter, compared to analysts’ expectations of $1.29 billion. Cerner had a net margin of 13.37% and a return on equity of 18.03%. The business’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.59 EPS.
Several equities analysts have commented on CERN shares. Royal Bank of Canada started coverage on Cerner in a research report on Tuesday, September 19th. They set a “top pick” rating and a $84.00 price objective for the company. KeyCorp reissued a “buy” rating and set a $76.00 price objective on shares of Cerner in a research report on Friday, September 22nd. Zacks Investment Research lowered Cerner from a “hold” rating to a “sell” rating in a research report on Tuesday, September 26th. Cantor Fitzgerald reissued a “buy” rating and set a $77.00 price objective on shares of Cerner in a research report on Tuesday, October 10th. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $77.00 price objective on shares of Cerner in a research report on Thursday, October 12th. Fifteen analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $69.94.
In other news, President Zane M. Burke sold 50,000 shares of the firm’s stock in a transaction on Wednesday, December 13th. The stock was sold at an average price of $70.00, for a total transaction of $3,500,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Clifford W. Illig sold 4,000 shares of the firm’s stock in a transaction on Tuesday, November 7th. The shares were sold at an average price of $65.96, for a total value of $263,840.00. Following the transaction, the chairman now owns 1,229,719 shares of the company’s stock, valued at $81,112,265.24. The disclosure for this sale can be found here. Insiders have sold 788,000 shares of company stock valued at $52,190,800 over the last 90 days. Corporate insiders own 13.11% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CERN. Victory Capital Management Inc. increased its holdings in Cerner by 16.1% in the 2nd quarter. Victory Capital Management Inc. now owns 31,298 shares of the company’s stock worth $2,080,000 after buying an additional 4,340 shares in the last quarter. Robeco Institutional Asset Management B.V. increased its holdings in Cerner by 34.1% in the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 15,075 shares of the company’s stock worth $1,002,000 after buying an additional 3,837 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Cerner by 6.4% in the 2nd quarter. Principal Financial Group Inc. now owns 453,958 shares of the company’s stock worth $30,175,000 after buying an additional 27,420 shares in the last quarter. Pacad Investment Ltd. bought a new stake in Cerner in the 2nd quarter worth about $130,000. Finally, Oppenheimer & Co. Inc. increased its holdings in Cerner by 3.9% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 30,074 shares of the company’s stock worth $1,999,000 after buying an additional 1,119 shares in the last quarter. Institutional investors own 81.82% of the company’s stock.
Cerner (CERN) opened at $70.53 on Wednesday. The company has a current ratio of 2.77, a quick ratio of 2.75 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $22,939.96, a price-to-earnings ratio of 35.09, a price-to-earnings-growth ratio of 2.07 and a beta of 0.94. Cerner has a 52-week low of $47.09 and a 52-week high of $73.86.
TRADEMARK VIOLATION NOTICE: “$0.61 EPS Expected for Cerner Co. (CERN) This Quarter” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/01/13/0-61-eps-expected-for-cerner-co-cern-this-quarter.html.
Cerner Company Profile
Cerner Corporation (Cerner) is a supplier of healthcare information technology (HCIT). The Company offers a range of intelligent solutions and services that support the clinical, financial and operational needs of organizations of all sizes. The Company’s segments include Domestic and Global. The Domestic segment includes revenue contributions and expenditures associated with business activity in the United States.
Get a free copy of the Zacks research report on Cerner (CERN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cerner Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerner and related companies with MarketBeat.com's FREE daily email newsletter.